Just when it looked as if Congress could finally enact the much-needed anti-opioid legislation, Big Pharma tried to gum up the works.

The important opioid legislation in the works for more than a year includes truly urgent provisions — including a measure that should make it harder for drug dealers to import deadly fentanyl from China via the U.S. Postal Service and one that expands Medicaid coverage to help infants born addicted to drugs.

And yet the pharmaceutical industry tried to hijack the bill for a $4 billion windfall.

Along with others, U.S. Sen. Rob Portman, R-Ohio, one of the main authors of this bill, opposed adding the amendment sought by the pharmaceutical industry. Fortunately, it appears that the outcry over this unwarranted intrusion on good legislation has succeeded in driving Big Pharma’s amendment out of the bill in conference committee.

Advertise with us

The bill — minus the lobbying legerdemain of the pharmaceutical industry — has been passed by the House and is expected to be passed soon by the Senate and signed by the president.

A budget bill passed earlier this year created a $4 billion discount for certain Medicare beneficaries’ prescription coverage. The drug companies want to get back the $4 billion. Hence, the industry’s proposed amendment.

The package of opioid-related bills wending its way through the Senate and House is the largest and most comprehensive measure aimed at stemming the opioid death toll yet. It is an outrage — but exactly what we’ve come to expect out of the Washington, D.C., swamp — that Congress would even consider merging these two issues.

It would have been a tragic irony that a bill designed to battle the opioid epidemic would be used to further pad the wealth of the industry whose negligence and greed contributed so much to the opioid epidemic in the first place.